Envudeucitinib (FTP-637): A Comprehensive Clinical and Strategic Analysis of a Next-Generation Allosteric TYK2 Inhibitor

Executive Summary

Envudeucitinib (also known as FTP-637 and ESK-001) is an investigational, oral, small-molecule drug representing a next-generation therapeutic approach for immune-mediated diseases. It functions as a highly selective, allosteric inhibitor of Tyrosine Kinase 2 (TYK2), a key intracellular signaling enzyme. By binding to the regulatory pseudokinase (JH2) domain of TYK2, Envudeucitinib locks the enzyme in an inactive state, thereby disrupting downstream signaling of critical pro-inflammatory cytokines, including Interleukin-23 (IL-23), Interleukin-12 (IL-12), and Type I interferons. This precise mechanism is designed to offer a superior therapeutic window, maximizing efficacy while minimizing the off-target effects associated with broader-acting Janus kinase (JAK) inhibitors.

Originally developed by Fronthera U.S. Pharmaceuticals LLC, the asset is now under the stewardship of Alumis, Inc., a late-stage biopharmaceutical company that is advancing it through pivotal clinical trials. The lead indication for Envudeucitinib is moderate-to-severe plaque psoriasis, a chronic autoimmune condition with a significant unmet need for safe and effective oral therapies.

The clinical development program has yielded highly promising results. The Phase 2 STRIDE study successfully demonstrated proof-of-concept, with the highest dose (40 mg twice daily) achieving a statistically and clinically significant Psoriasis Area and Severity Index (PASI) 75 response rate of 64% at 12 weeks, compared to 0% for placebo. More significantly, data from a 52-week open-label extension (OLE) study revealed not only durable but continually improving efficacy. At one year, 61% of patients achieved PASI 90 (near-complete skin clearance) and 39% achieved PASI 100 (complete skin clearance). A remarkable 62% of patients showed continued improvement in their PASI response from week 12 to week 52. Throughout this period, the drug maintained a favorable safety and tolerability profile, with no evidence of the adverse events commonly associated with pan-JAK inhibitors.

Building on this success, Alumis has fully enrolled a pivotal Phase 3 program, ONWARD, which includes two global trials comparing Envudeucitinib to both placebo and the established oral therapy apremilast (Otezla). Topline data from this program, expected in the first quarter of 2026, represents the most critical near-term catalyst and will be the ultimate determinant of the drug's registrational path and competitive standing.

Strategically, Alumis is positioning Envudeucitinib as a potential "best-in-class" oral TYK2 inhibitor, aiming to challenge the first-in-class market leader, deucravacitinib (Sotyktu). The company is also exploring the drug's potential as a platform therapy for autoimmunity by conducting a Phase 2b trial (LUMUS) in Systemic Lupus Erythematosus (SLE), with data expected in the third quarter of 2026. Proactive lifecycle management is also underway with the development of a once-daily modified-release formulation.

In conclusion, Envudeucitinib is a scientifically well-differentiated asset with a compelling clinical profile characterized by high-level, durable, and improving efficacy in psoriasis, coupled with a promising safety record. Its future hinges on the successful outcome of the Phase 3 ONWARD program, which, if positive, could position Envudeucitinib as a leading oral treatment for psoriasis and potentially a range of other debilitating autoimmune diseases.

1.0 Molecular Profile and Developmental Genesis

This section establishes the fundamental identity of the Envudeucitinib molecule, detailing its nomenclature, physicochemical properties, and the corporate history that has shaped its developmental trajectory.

1.1 Identification, Nomenclature, and Physicochemical Properties

The investigational drug is a small-molecule therapeutic agent that has been identified by several names throughout its development cycle. Its earliest development code was FTP-637.[1] It is also widely known by the code ESK-001.[1] In a key step toward potential commercialization, the United States Adopted Names (USAN) Council has officially designated "Envudeucitinib" as the nonproprietary (generic) name for the molecule.[1]

Pharmacologically, Envudeucitinib is classified as an inhibitor of Tyrosine-protein kinase 2 (TYK2), a member of the Janus kinase (JAK) family of enzymes.[1] Its chemical structure and properties have been precisely characterized, as detailed in Table 1. A notable feature of its structure is the incorporation of six deuterium atoms, a medicinal chemistry strategy known as deuteration. The molecular formula is therefore $C_{22}H_{18}D_{6}N_{6}O_{3}$, distinguishing it from its non-deuterated analogue, which has the formula $C_{22}H_{24}N_{6}O_{3}$.[1] This modification results in a molar mass of 426.506 g·mol−1.[2]

Table 1: Key Drug Identifiers for Envudeucitinib (FTP-637)

Identifier Type	Value	Source(s)
Nonproprietary Name	Envudeucitinib	1
Development Codes	FTP-637, ESK-001	1
CAS Registry Number	2417135-66-9	1
Molecular Formula	$C_{22}H_{18}D_{6}N_{6}O_{3}$	2
Molar Mass	426.506 g·mol−1	2
IUPAC Name	N-(4-{2-methoxy-3-[1-(trideuteriomethyl)-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide	2
InChIKey	FKCATCQHVCOBCX-WFGJKAKNSA-N	1
PubChem CID	158715582	2
UNII	KD2MDJ4GAB	2
KEGG	D13123	2

1.2 Corporate Lineage: From Fronthera to Alumis, Inc.

The developmental journey of Envudeucitinib began at Fronthera U.S. Pharmaceuticals LLC, which is credited as the originator organization for the compound.[2] The drug is now owned and being actively advanced through late-stage clinical development by Alumis, Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company headquartered in South San Francisco with a strategic focus on developing oral therapies for immune-mediated diseases.[1]

The transfer of the asset was formalized through a Stock Purchase Agreement dated March 5, 2021.[7] In this transaction, an entity named FL2021-001, Inc. (the "Purchaser," which would become Alumis) acquired FronThera U.S. Holdings, Inc. from its parent, FronThera International Group Limited (the "Seller").[7] The deal was structured with a base initial consideration of $60 million.[7] This agreement was strategically designed to transfer the full rights to key intellectual property and products, including Envudeucitinib, to the purchaser, while other assets and liabilities were transferred to Haisco Pharmaceutical Group.[7]

This corporate transition represents a well-defined and common strategy within the biotechnology ecosystem. An early-stage company like Fronthera invests in the high-risk discovery and initial development phases to generate a promising asset and de-risk it to a certain milestone, such as the completion of preclinical or early clinical studies. The asset is then acquired by a more specialized, well-capitalized company like Alumis, which possesses the expertise and financial resources required to execute large, expensive, and complex late-stage global clinical trials and navigate the path to commercialization. The initial consideration of $60 million for an early-stage asset reflects a significant vote of confidence in its potential and was likely supplemented by substantial downstream milestone payments and royalties contingent on clinical and commercial success. This strategic handover places the asset in the hands of a corporate entity best equipped to maximize its value through pivotal development.

1.3 Strategic Rationale for Deuteration and Formulation Development

The chemical structure of Envudeucitinib is intentionally modified through deuteration, a process where specific hydrogen atoms are replaced by their heavier, stable isotope, deuterium.[2] This is a deliberate medicinal chemistry strategy employed to alter a drug's metabolic profile. The carbon-deuterium bond is stronger than the carbon-hydrogen bond, making it more resistant to metabolic cleavage by enzymes, particularly cytochrome P450 enzymes in the liver. The goal of this modification is typically to slow the rate of drug metabolism, which can lead to an improved pharmacokinetic (PK) profile. Potential benefits include a longer half-life, increased drug exposure (Area Under the Curve, or AUC), and more stable plasma concentrations, which can translate into improved efficacy, a better safety profile, or more convenient dosing regimens.

In parallel with its pivotal Phase 3 program, which utilizes an immediate-release (IR) formulation dosed twice daily (BID), Alumis is actively developing a once-daily (QD) modified-release (MR) oral formulation of Envudeucitinib.[9] This represents a forward-thinking and aggressive lifecycle management strategy. For chronic conditions like psoriasis, where long-term adherence is critical, dosing convenience is a major factor in physician prescribing decisions and patient preference. By investing in the development of a once-daily option while the twice-daily formulation is still under investigation, Alumis is proactively addressing a potential competitive disadvantage against other oral therapies that offer once-daily dosing. This parallel development track is capital-intensive but strategically astute, as it shortens the timeline to bring an improved formulation to market. A successful MR formulation could be introduced shortly after the initial approval of the IR version, helping to rapidly establish a strong market position, enhance patient adherence, and maximize the commercial potential of the Envudeucitinib franchise.

2.0 Pharmacological Profile: Precision Targeting of the TYK2 Pseudokinase Domain

The therapeutic potential of Envudeucitinib is rooted in its highly specific and novel mechanism of action. This section details the molecular interactions, the downstream signaling consequences, and the key advantages this precision-targeting approach is designed to confer over previous generations of immunomodulatory drugs.

2.1 Mechanism of Action: Allosteric Inhibition of the JH2 Domain

Envudeucitinib is a highly selective, orally administered, allosteric inhibitor of tyrosine kinase 2 (TYK2).[3] TYK2 is an intracellular enzyme and a member of the Janus kinase (JAK) protein family, which also includes JAK1, JAK2, and JAK3. These kinases are essential for transducing signals from cytokine receptors on the cell surface to the nucleus, thereby regulating gene expression involved in immunity and inflammation.[13]

The mechanism of Envudeucitinib is fundamentally different from that of traditional JAK inhibitors. All JAK family members possess a catalytic kinase domain, known as the JH1 domain, which contains a highly conserved ATP-binding site. First-generation JAK inhibitors are ATP-competitive, meaning they bind within this active site to block the enzyme's function.[13] However, because this site is structurally similar across all JAK family members, these inhibitors often lack selectivity, leading to the simultaneous blockade of multiple JAKs.

Envudeucitinib circumvents this issue through its unique allosteric mechanism. Instead of targeting the conserved JH1 domain, it binds to a distinct site on the regulatory pseudokinase domain, known as the JH2 domain.[13] The JH2 domain, which lacks catalytic activity itself, acts as a regulatory module that controls the activity of the JH1 domain. By binding to this allosteric site on the JH2 domain, Envudeucitinib stabilizes the TYK2 protein in an inactive conformation. This "locking" action prevents the necessary conformational changes that would normally allow the JH1 domain to become catalytically active, thus effectively shutting down the enzyme's function without directly competing with ATP.[13]

2.2 Downstream Signaling Consequences: Interruption of IL-23/IL-12 and Type I IFN Pathways

The therapeutic effects of Envudeucitinib stem directly from its ability to block the function of TYK2, which serves as a critical signaling partner for a specific set of cytokine receptors. TYK2 is essential for mediating the intracellular signals of key pro-inflammatory cytokines, most notably Interleukin-23 (IL-23), Interleukin-12 (IL-12), and Type I interferons (IFNs).[2]

When these cytokines bind to their receptors on the surface of immune cells, TYK2 (often paired with another JAK like JAK2) becomes activated and phosphorylates the receptor chains. This creates docking sites for Signal Transducer and Activator of Transcription (STAT) proteins. The STATs are then phosphorylated by the JAKs, causing them to dimerize, translocate to the nucleus, and initiate the transcription of hundreds of inflammation-related genes.[13]

By inhibiting TYK2, Envudeucitinib effectively breaks this chain of events. It interrupts these specific signaling cascades, preventing STAT activation and the subsequent expression of pro-inflammatory genes.[13] The IL-23/IL-17 signaling axis is recognized as a central pathway in the immunopathogenesis of psoriasis. IL-23 promotes the differentiation and maintenance of Th17 cells, which are major producers of the inflammatory cytokine IL-17. By blocking the IL-23 receptor signaling pathway, TYK2 inhibition effectively dampens the entire pathogenic axis, leading to a reduction in the inflammation that causes psoriatic lesions.[15] This targeted disruption of key disease-driving pathways forms the scientific basis for Envudeucitinib's efficacy in psoriasis and other autoimmune disorders.

2.3 The Selectivity Advantage: Differentiation from Pan-JAK and Orthosteric TYK2 Inhibitors

The allosteric binding of Envudeucitinib to the structurally unique JH2 domain of TYK2 is the key to its high degree of selectivity. This mechanism allows it to potently inhibit TYK2 while having minimal activity against the other JAK family members (JAK1, JAK2, and JAK3).[13] This selectivity is a major point of differentiation and the foundation of the drug's anticipated favorable safety profile.

This contrasts sharply with first-generation, non-selective "pan-JAK" inhibitors. Because these drugs target the conserved ATP-binding site, they inhibit multiple JAKs simultaneously. While this can produce a powerful anti-inflammatory effect, it also leads to the blockade of a wide array of cytokine pathways that are essential for normal physiological functions, such as host defense and hematopoiesis (the formation of blood cells). Consequently, pan-JAK inhibitors are associated with a range of dose-limiting toxicities and safety concerns, including serious infections, hematologic abnormalities (e.g., anemia, neutropenia), and thromboembolic events, which have led to regulatory warnings.[15]

The entire investment and development thesis for Envudeucitinib is built upon a clear scientific hypothesis: that its highly selective, allosteric inhibition of the TYK2 JH2 domain will yield a superior benefit-risk profile compared to all other inhibitors of the JAK-STAT pathway. This is not merely a point of molecular distinction; it is the central pillar of the drug's aspiration to be a "best-in-class" therapy. Every piece of clinical data, particularly safety data, must be interpreted through this lens. The low rate of adverse events, low discontinuation rate, and notable absence of typical JAK-related safety signals observed in the Phase 2 STRIDE study and its long-term extension provide the first crucial clinical validation of this foundational hypothesis.[3] The definitive confirmation of this superior safety profile now awaits the large, robust dataset from the pivotal Phase 3 ONWARD program.

Furthermore, the specific pathways targeted by Envudeucitinib—IL-23, IL-12, and particularly Type I IFN—are implicated in a wide spectrum of autoimmune diseases beyond psoriasis.[14] The strategic decision by Alumis to initiate a large Phase 2b trial in Systemic Lupus Erythematosus (SLE), a disease where the Type I IFN pathway is a well-established pathogenic driver, is a direct and logical extension of the drug's mechanism of action.[21] This demonstrates that Alumis views Envudeucitinib not simply as a "psoriasis drug," but as a potential pipeline-in-a-product—a platform molecule with the potential to become a franchise therapy for multiple TYK2-mediated autoimmune diseases.

3.0 Early-Stage Clinical Validation: The Phase 1 Program

Before advancing into patient populations, Envudeucitinib underwent rigorous early-stage clinical testing in healthy volunteers. This Phase 1 program was designed to establish the drug's initial safety, tolerability, and pharmacokinetic profile, providing the essential data needed to support and de-risk subsequent development.

3.1 Study Design and Objectives (ACTRN12621000011886)

The first-in-human study for Envudeucitinib was a comprehensive Phase 1 trial registered under the identifier ACTRN12621000011886. It was structured as a two-part, randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers.[22] The design was meticulously planned to answer key questions about the drug's behavior in humans, as summarized in Table 2.

• Part A (Single Ascending Dose - SAD): This part of the study was designed to evaluate the safety and PK of single oral doses of Envudeucitinib. Cohorts of volunteers received escalating doses of the drug, administered as an oral solution, ranging from 5 mg to 150 mg, or a matching placebo. This part also included a dedicated open-label, two-period crossover cohort to specifically assess the effect of a high-fat meal on the drug's absorption and pharmacokinetics.[23]
• Part B (Multiple Ascending Dose - MAD): Following the evaluation of single doses, this part assessed the drug's safety and PK profile after repeated administration. Cohorts received either once-daily or twice-daily doses of Envudeucitinib or placebo for seven consecutive days. The dose levels for the MAD cohorts were selected based on a careful review of the emerging safety and PK data from the SAD cohorts.[23]

The primary objective of the trial was to thoroughly assess the safety and tolerability of Envudeucitinib. This was accomplished through intensive monitoring of adverse events (AEs), regular physical examinations, frequent measurement of vital signs, electrocardiograms (ECGs), and comprehensive clinical laboratory tests (hematology, blood biochemistry, and urinalysis).[23]

The secondary objectives were to characterize the drug's pharmacokinetic and pharmacodynamic profile. This involved collecting frequent blood samples to measure plasma drug concentrations over time, as well as urine and feces samples to understand the routes of excretion. Furthermore, the study aimed to assess pharmacodynamic (PD) biomarkers to confirm that the drug was engaging its target as intended. This included measuring changes in lymphocyte counts and the phosphorylation of STAT proteins (pSTAT), which is a direct downstream marker of TYK2 pathway activity.[23]

Table 2: Summary of Phase 1 Study Design and Cohorts (ACTRN12621000011886)

Study Part	Cohort Type	Dose Range	Dosing Regimen	Key Assessments
Part A	Single Ascending Dose (SAD)	5 mg – 150 mg	Single oral dose	Safety, Tolerability, Pharmacokinetics (PK)
Part A	Food-Effect	Dose based on SAD data	Single dose (fasted vs. fed)	Safety, Tolerability, PK
Part B	Multiple Ascending Dose (MAD)	Dose based on SAD data	Once or twice daily for 7 days	Safety, Tolerability, PK, Pharmacodynamics (PD)

3.2 Safety, Tolerability, and Pharmacokinetic Profile in Healthy Volunteers

The results from the Phase 1 program provided the necessary foundation to proceed with development in patients. The data demonstrated that Envudeucitinib was generally safe and well-tolerated in healthy volunteers across the range of single and multiple doses tested.[20] The pharmacokinetic analysis revealed that the drug exhibited linear, dose-dependent PK characteristics, meaning that as the dose was increased, the drug exposure in the body increased proportionally. This predictability is a highly desirable attribute for a new drug candidate.[25]

Crucially, the pharmacodynamic assessments confirmed that Envudeucitinib achieved high levels of target inhibition in a dose- and concentration-dependent manner.[25] The comprehensive data package generated from this trial was instrumental in building a robust pharmacokinetic/pharmacodynamic (PK/PD) model.

While the primary purpose of a Phase 1 study is to establish safety, its strategic value lies in its ability to inform the design of subsequent, more complex trials. The SAD/MAD design, with its wide dose range and inclusion of detailed PD markers, was not merely a safety check but a rigorous scientific exercise. The PK/PD model derived from this data allowed Alumis to accurately predict how a specific dose of Envudeucitinib would translate to a particular level of TYK2 inhibition over a 24-hour period. This data-driven approach was essential for confidently selecting the dose range for the Phase 2 STRIDE trial (10 mg once-daily to 40 mg twice-daily).[20] By entering Phase 2 with a strong understanding of the dose-exposure-response relationship, the company significantly de-risked the much more expensive and lengthy proof-of-concept study in patients, increasing the probability of a successful outcome.

4.0 Clinical Program in Plaque Psoriasis: Establishing Efficacy and Durability

The cornerstone of Envudeucitinib's development is its extensive clinical program in moderate-to-severe plaque psoriasis. This program, from the initial dose-ranging Phase 2 study to the ongoing pivotal Phase 3 trials, is designed to comprehensively define the drug's efficacy, safety, and long-term durability in its lead indication.

4.1 The Phase 2 STRIDE Study: Dose-Ranging and Proof-of-Concept

The STRIDE study (NCT05600036) served as the critical proof-of-concept trial for Envudeucitinib in psoriasis. It was a robustly designed Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study that enrolled 228 adult patients with moderate-to-severe plaque psoriasis.[9]

• Trial Design and Treatment Arms: Patients were randomized to one of six treatment groups for a 12-week period. Five of these groups received active treatment with Envudeucitinib at varying doses and frequencies: 10 mg once daily (QD), 20 mg QD, 40 mg QD, 20 mg twice daily (BID), and 40 mg BID. The sixth group received a matching placebo, serving as the control arm.[20]
• Endpoints: The primary efficacy endpoint was the proportion of patients achieving at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at Week 12, compared to the placebo group. Key secondary endpoints included higher thresholds of skin clearance, such as PASI 90 and PASI 100 (complete clearance), as well as the proportion of patients achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear).[20]
• Efficacy Outcomes: The STRIDE trial successfully met its primary endpoint and demonstrated a clear dose-dependent therapeutic effect across all clinical measures.[1] The maximal efficacy was observed in the highest dose arm, 40 mg BID. In this group, 64.1% of patients achieved a PASI 75 response at Week 12, a result that was both statistically and clinically highly significant compared to the 0% response rate seen in the placebo group ($P <.0001$).[1] Further data presented from the study highlighted that approximately 88% of patients in this high-dose arm achieved a PASI 90 response, indicating near-complete skin clearance for a vast majority of participants.[28]
• Safety and Tolerability: Throughout the 12-week treatment period, Envudeucitinib was found to be generally safe and well-tolerated across all dose levels.[20] The overall incidence of treatment-emergent adverse events (TEAEs) was comparable between the active treatment groups and the placebo group, with the majority of events being mild or moderate in severity. The most frequently reported AEs were consistent with those seen in trials for similar immunomodulators and included headache, upper respiratory tract infection, nasopharyngitis, and COVID-19.[20] Critically, there was no evidence of the adverse events characteristically associated with broader JAK inhibition, such as significant hematologic abnormalities or thromboembolic events, reinforcing the safety advantage of the drug's selective mechanism.[20] The rate of discontinuation due to adverse events was very low, at just 2.6% for patients receiving Envudeucitinib.[26] A small number of serious adverse events (SAEs) were reported but were all deemed by investigators to be unrelated to the study drug; these included events such as bone fractures, a case of coronary artery occlusion, and a case of colitis and enteritis.[27]

4.2 Long-Term Outcomes: The 52-Week STRIDE Open-Label Extension (OLE)

To assess the long-term safety and durability of response, patients who completed the 12-week STRIDE study were eligible to enroll in an open-label extension (OLE) study (NCT05739435). In this phase, 165 patients continued treatment with Envudeucitinib, receiving either 40 mg QD or 40 mg BID.[3] The data from this OLE have been a defining feature of the drug's clinical profile.

• Sustained and Improving Efficacy: The OLE results demonstrated that the clinical benefits of Envudeucitinib are not only maintained but, for a majority of patients, actually improve with continued treatment. This finding is a powerful differentiator in the crowded psoriasis market. After 52 weeks of continuous treatment with the 40 mg BID dose, the efficacy results were robust, as shown in Table 3 [3]:
• PASI 75: 78% of patients
• PASI 90: 61% of patients
• PASI 100 (complete skin clearance): 39% of patients
• sPGA 0 (clear skin): 39% of patients

The most compelling finding from the OLE was that 62% of patients showed a continued improvement in their PASI response over time when their 52-week result was compared to their 12-week result from the initial STRIDE study.[3] While many effective therapies demonstrate a peak effect that is subsequently maintained, an improving effect over such a long period suggests a deeper, more profound level of disease modification. This clinical narrative—that the drug works well initially and then continues to get better for many patients over the course of a year—is a powerful and unusual result that will form a cornerstone of Alumis's argument for a "best-in-class" profile.

• Patient-Reported Outcomes and Long-Term Safety: The improvements in clinical signs were mirrored by significant benefits in patient-reported outcomes. After 52 weeks, approximately 80% of patients reported a pruritus (itch) score of less than 4 on a numerical rating scale, and 61% achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating that their psoriasis had little to no impact on their quality of life.[3] The favorable safety profile established in the 12-week study was maintained throughout the 52-week OLE. The overall discontinuation rate due to AEs remained low at 3.7%, and no new safety signals or clinically concerning trends in laboratory parameters or ECGs emerged with longer-term exposure.[3] This long-term safety data, summarized in Table 4, further validates the "mechanism-to-safety" hypothesis of selective TYK2 inhibition.

Table 3: Key Efficacy Endpoints from the Phase 2 STRIDE Study and 52-Week OLE (40 mg BID Dose)

Efficacy Endpoint	Placebo (Week 12)	Envudeucitinib (Week 12)	Envudeucitinib (Week 52 OLE)
PASI 75	0%	64%	78%
PASI 90	N/A	~88%*	61%
PASI 100	N/A	N/A	39%
sPGA 0/1	N/A	N/A	N/A (sPGA 0 was 39%)
*Note: PASI 90 data at Week 12 is from a conference presentation and may represent a different analysis subset than the primary publication.

Table 4: Summary of Adverse Events in the Phase 2 STRIDE Program

Adverse Event Profile	Placebo (12 Weeks)	Envudeucitinib (All Doses, 12 Weeks)	Envudeucitinib (OLE, 52 Weeks)
Most Common TEAEs	Incidence similar to active drug	Headache, URTI, Nasopharyngitis, COVID-19	Profile consistent with 12-week study
JAK-class AEs	None reported	None reported	None reported
Discontinuation due to AE	N/A	2.6%	3.7%
Serious AEs (unrelated)	None reported	Fractures, coronary artery occlusion, colitis, dermatitis	No new signals emerged

4.3 The Pivotal Phase 3 ONWARD Program

Building on the strength of the Phase 2 data, Alumis has initiated and fully enrolled the ONWARD program, a global pivotal Phase 3 clinical program designed to support regulatory submissions for approval.[9]

• Program Architecture: The program consists of two identical, large-scale, multi-center, randomized, double-blind trials named ONWARD1 and ONWARD2.[1] Each trial is designed to enroll approximately 840 patients, for a total program size of over 1,700 individuals with moderate-to-severe plaque psoriasis.[29]
• Trial Design and Comparators: The trials employ a 2:1:1 randomization scheme, where patients are assigned to receive either Envudeucitinib 40 mg BID, a placebo, or the active comparator apremilast (Otezla).[12] The placebo-controlled period runs for the first 16 weeks, while the comparison against apremilast extends for the full 24 weeks of the main trial period. The inclusion of apremilast is a bold and strategically vital decision. Alumis is not merely aiming for approval based on superiority to placebo; it is proactively generating head-to-head data against the most widely prescribed oral therapy for psoriasis. This strategy directly follows the successful playbook used for the approval and launch of deucravacitinib. A successful outcome on key secondary endpoints versus apremilast would provide a powerful, evidence-based marketing claim and could significantly influence physician prescribing habits and facilitate favorable formulary access with payers, directly targeting Otezla's established market share.
• Endpoints and Timelines: The co-primary efficacy endpoints for regulatory approval are the proportion of patients achieving PASI 75 and an sPGA score of 0/1 at Week 16, comparing Envudeucitinib to placebo.[9] A host of key secondary endpoints will assess higher efficacy bars (PASI 90, PASI 100) and compare Envudeucitinib's performance against apremilast at both Week 16 and Week 24.[29] Patients who complete the 24-week trials will have the option to enroll in a long-term extension study, ONWARD3, to gather further data on durability and safety.[29] Alumis has announced that patient enrollment for the ONWARD program is complete and anticipates reporting topline data in the first quarter of 2026.[1] This data readout is the single most important near-term catalyst for the drug and for Alumis as a company.

5.0 Pipeline Expansion: Targeting Systemic Autoimmune Disease

Leveraging the strong scientific rationale behind TYK2 inhibition, Alumis is strategically expanding the clinical development of Envudeucitinib beyond dermatology. This expansion into systemic autoimmune diseases underscores the company's vision for the asset as a broad-spectrum immunomodulatory agent.

5.1 Rationale for TYK2 Inhibition in Systemic Lupus Erythematosus (SLE)

Alumis is actively developing Envudeucitinib for the treatment of systemic immune-mediated disorders, with SLE being the second lead indication after psoriasis.[10] The scientific rationale for this expansion is exceptionally strong and directly linked to the drug's mechanism of action. While the IL-23 pathway is central to psoriasis, the Type I interferon (IFN) signaling pathway is a well-established and critical pathogenic driver in the majority of patients with SLE.[16] The production of Type I IFNs by plasmacytoid dendritic cells leads to a cascade of immune activation, autoantibody production, and tissue damage that characterize the disease. As TYK2 is an essential enzyme for transducing signals from the Type I IFN receptor, its inhibition by Envudeucitinib offers a direct and targeted approach to quell this central disease pathway. By blocking this signaling, Envudeucitinib aims to correct the fundamental immune dysregulation at the heart of SLE, potentially leading to a reduction in disease activity and clinical symptoms.[16]

5.2 The Phase 2b LUMUS Trial: Design and Primary Endpoint Analysis

To test this hypothesis clinically, Alumis has initiated and completed patient enrollment in the global LUMUS trial (NCT05966480), a significant Phase 2b study.[1]

• Trial Design: LUMUS is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of multiple doses of Envudeucitinib in adults with moderately-to-severely active SLE.[21]
• Patient Population and Enrollment: The trial has successfully enrolled its target of 408 patients with autoantibody-positive SLE, a substantial size for a Phase 2b study in this indication, reflecting a commitment to generating a robust dataset.[1]
• Treatment and Duration: Participants in the study will receive either Envudeucitinib or a placebo for a treatment period of 48 weeks.[1]
• Primary Endpoint: The primary endpoint is the assessment of improvement in overall disease activity at Week 48, measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rate.[1] The BICLA is a stringent and validated composite endpoint accepted by regulatory agencies for lupus trials.
• Timeline: Alumis has guided that topline data from the LUMUS trial are expected in the third quarter of 2026.[1]

While the mechanistic rationale is strong, the pursuit of an indication in SLE represents a high-risk, high-reward endeavor. The history of drug development in lupus is fraught with clinical trial failures, owing to the heterogeneity of the disease and the difficulty in demonstrating a clear treatment effect. The choice of the rigorous BICLA endpoint over 48 weeks sets a high bar for success. However, a positive outcome in the LUMUS trial would be transformative for Alumis. It would not only open up a multi-billion dollar market with immense unmet medical need but would also provide powerful validation of Envudeucitinib's mechanism as a platform for treating a range of TYK2-mediated diseases, significantly increasing the asset's overall value.

5.3 Potential in Other Immune-Mediated Indications

The company's pipeline strategy suggests a broad vision for TYK2 inhibition. Official documentation lists active indications for Envudeucitinib as plaque psoriasis, psoriasis of the scalp, and SLE.[1] Additionally, non-infectious posterior uveitis and intermediate uveitis are listed as "inactive indications," which may suggest these were areas of early interest or could be targets for future exploration.[1] Indeed, Alumis has since initiated a Phase 2 proof-of-concept study (OPTYK-1) in non-infectious uveitis, confirming its interest in this ophthalmologic inflammatory condition.[25]

The depth of Alumis's commitment to the TYK2 target is further evidenced by its development of a second, distinct allosteric TYK2 inhibitor, A-005.[24] This molecule has been specifically engineered to be CNS-penetrant and is being developed for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson's disease.[24] The creation of a second, differentiated asset targeting TYK2 demonstrates that Alumis's core expertise is not limited to the Envudeucitinib molecule itself, but extends to the broader biology of TYK2 and the specialized chemistry required to design highly selective allosteric inhibitors. This suggests a sustainable research and development engine and a long-term corporate strategy built around mastering this specific target class, de-risking the company from being solely dependent on a single asset and making it more attractive to long-term investors.

6.0 Competitive and Market Landscape Analysis

Envudeucitinib is entering a dynamic and increasingly competitive therapeutic landscape for immune-mediated diseases. Its ultimate commercial success will depend not only on its own clinical profile but also on its positioning relative to the established market leader, other pipeline competitors, and the broader array of available oral and biologic therapies.

6.1 Deucravacitinib (Sotyktu) as the Market Benchmark

The primary competitor and benchmark for Envudeucitinib is deucravacitinib (BMS-986165), marketed by Bristol-Myers Squibb (BMS) as Sotyktu. Sotyktu was the first-in-class oral, selective, allosteric TYK2 inhibitor to gain regulatory approval, receiving clearance from the U.S. Food and Drug Administration (FDA) in September 2022 for the treatment of adults with moderate-to-severe plaque psoriasis.[15]

• Commercial Performance: Sotyktu's launch has successfully validated the commercial potential of the TYK2 inhibitor class. The drug generated $170 million in revenue in its first full year on the market (FY 2023) and a total of $274 million since its launch.[34] BMS has issued ambitious forecasts, suggesting that peak annual sales for Sotyktu could reach as high as $4 billion.[19] This is within an overall oral systemic psoriasis drug market estimated to be worth approximately $25.7 billion.[34]
• Clinical Profile: Sotyktu established its clinical credentials in the pivotal POETYK PSO-1 and POETYK PSO-2 trials, where it demonstrated clear superiority over both placebo and the active comparator, apremilast.[33] Furthermore, BMS has presented long-term extension data showing that Sotyktu's efficacy is durable and its safety profile remains consistent over five years of continuous treatment, with no new safety signals emerging.[37] This extensive long-term dataset sets a very high clinical bar that any new entrant, including Envudeucitinib, will be expected to meet or exceed.
• Significance: The successful development, approval, and launch of Sotyktu have been instrumental in paving the way for molecules like Envudeucitinib. It has validated TYK2 as a safe and effective therapeutic target, educated physicians and payers about this novel mechanism, and established a clear regulatory and commercial pathway. It also serves as the direct benchmark against which Envudeucitinib's clinical profile will be judged.

6.2 Analysis of Key Pipeline Competitors

The success of Sotyktu has spurred intense activity in the TYK2 inhibitor space, and Alumis faces competition from several other companies developing next-generation assets, as detailed in Table 6.[8]

• Takeda (via Nimbus Therapeutics): Takeda is developing TAK-279 (zasocitinib), another oral, selective, allosteric TYK2 inhibitor. In a Phase 2b study, TAK-279 demonstrated a strong dose-dependent response, with the highest doses achieving PASI 75 in 67-68% of patients, leading to claims of potential "biologic-level efficacy." The drug has advanced into a Phase 3 program for both psoriasis and psoriatic arthritis, positioning it as a direct and formidable competitor to Envudeucitinib.[18]
• Pfizer: Pfizer is pursuing a different chemical strategy with two orthosteric TYK2 inhibitors: brepocitinib (PF-06700841) and ropsacitinib (PF-06826647). These molecules bind to the conserved ATP-binding site (JH1 domain) rather than the allosteric JH2 domain. Brepocitinib is a dual inhibitor of TYK2 and JAK1.[15] This mechanistic difference represents a key point of differentiation and a central scientific debate in the field. The market will ultimately determine whether the allosteric approach provides a tangible safety or efficacy advantage over the orthosteric one.
• Other Players: A number of other biotechnology companies, including Priovant Therapeutics, Galapagos, and Ventyx Biosciences, are also developing TYK2 or dual TYK2/JAK1 inhibitors for various autoimmune indications, contributing to a crowded and competitive pipeline.[8]

The market for oral psoriasis therapies is effectively a race to establish a "best-in-class" profile now that the "first-in-class" position is secured by Sotyktu. For Envudeucitinib to achieve significant market share, it cannot simply be non-inferior to Sotyktu; it must demonstrate a clear and clinically meaningful advantage. The primary battleground for this differentiation will be cross-trial comparisons of efficacy and safety data. Alumis's strategy will likely focus on leveraging its compelling OLE data, particularly the "improving response" narrative and the high rates of PASI 90 and PASI 100 achievement, to argue for superior deep and durable responses. Even small numerical advantages on these high-hurdle efficacy endpoints or in long-term safety could be pivotal in building a "best-in-class" commercial narrative.

Table 6: Competitive Landscape of Late-Stage Oral TYK2 Inhibitors in Psoriasis

Drug Name	Company	Mechanism	Development Phase	Key Reported Efficacy (PASI 75)
Envudeucitinib (ESK-001)	Alumis, Inc.	Allosteric TYK2 Inhibitor	Phase 3	64% at Week 12 (Phase 2)
Deucravacitinib (Sotyktu)	Bristol-Myers Squibb	Allosteric TYK2 Inhibitor	Approved	58% at Week 16 (Phase 3)
TAK-279 (Zasocitinib)	Takeda	Allosteric TYK2 Inhibitor	Phase 3	68% at Week 12 (Phase 2b)
Brepocitinib	Pfizer	Orthosteric TYK2/JAK1 Inhibitor	Phase 2b	N/A (Psoriasis program status unclear)
Ropsacitinib	Pfizer	Orthosteric TYK2 Inhibitor	Phase 2b	N/A (Psoriasis program status unclear)

6.3 Positioning Against Established Biologics and Oral Therapies

Beyond the direct competition from other TYK2 inhibitors, Envudeucitinib must carve out a position within the broader psoriasis treatment paradigm, which includes highly effective injectable biologics and other oral agents.

• Oral Convenience: The primary and most significant advantage of Envudeucitinib over the array of established injectable biologics (e.g., anti-TNF agents like Humira, anti-IL-17 agents like Cosentyx, and anti-IL-23 agents like Skyrizi) is the convenience of an oral pill. Many patients prefer an oral medication over self-injection, which can improve adherence and quality of life.[19]
• Efficacy vs. Biologics: The critical challenge for any oral therapy is to deliver efficacy that is competitive with these highly effective biologics. The term "biologic-like efficacy" has become a key goal for oral drug developers. The impressive rates of high-level skin clearance seen with Envudeucitinib in its 52-week OLE—with 61% of patients achieving PASI 90 and 39% achieving complete clearance (PASI 100)—suggest that it may indeed approach this level of performance, making it a compelling option for both patients and physicians seeking an oral alternative without a significant compromise on efficacy.[3]
• Competition with Apremilast (Otezla): Apremilast is an established oral therapy with a different mechanism of action (PDE4 inhibition). While it has a long track record of safety, its efficacy is generally considered more modest than that of biologics or TYK2 inhibitors. Deucravacitinib has already proven its superiority to apremilast in head-to-head trials, and Envudeucitinib's Phase 3 program is explicitly designed to generate similar data, which would position it as a superior oral option.[29]

7.0 Strategic Assessment and Forward Outlook

This final section synthesizes the preceding analysis to provide a forward-looking expert assessment of Envudeucitinib's clinical profile, strategic positioning, and long-term commercial potential.

7.1 Synthesis of Envudeucitinib's Clinical Profile: Strengths and Potential Risks

Envudeucitinib has emerged from mid-stage clinical development with a profile characterized by numerous strengths, balanced by the inherent risks of late-stage pharmaceutical development.

• Strengths:
• Differentiated Mechanism: Its highly selective, allosteric mechanism of action provides a strong scientific rationale for a superior safety profile.
• Compelling Efficacy: The Phase 2 data demonstrated robust efficacy, and the 52-week OLE data is particularly compelling, showing not only durable but also improving responses over time, with high rates of near-complete and complete skin clearance.
• Favorable Safety Profile: To date, the clinical program has revealed a clean safety profile, with no evidence of the class-specific adverse events associated with broader-acting JAK inhibitors.
• Robust Pivotal Program: The Phase 3 ONWARD program is well-designed, appropriately powered, and includes a commercially crucial active comparator (apremilast) to support a superiority claim.
• Strategic Pipeline Expansion: The mechanistically sound expansion into high-value indications like SLE demonstrates a clear vision for the asset as a platform therapy.
• Proactive Lifecycle Management: The parallel development of a once-daily formulation is a strategically sound move to maximize long-term commercial competitiveness.
• Potential Risks:
• Execution Risk: Conducting two large, global Phase 3 trials is a complex and expensive undertaking with inherent operational risks.
• High Competitive Bar: The incumbent, Sotyktu, has set a high benchmark for efficacy and has a multi-year head start in the market. Envudeucitinib must demonstrate clear differentiation to capture significant market share.
• Emergence of Safety Signals: While the safety profile is clean to date, the possibility of unforeseen or rare adverse events emerging in the much larger Phase 3 dataset cannot be ruled out.
• Pipeline Competition: The TYK2 inhibitor space is becoming crowded, with other well-funded competitors like Takeda also advancing promising assets into late-stage trials.
• Indication Expansion Risk: The LUMUS trial in SLE, while having a strong rationale, is in a therapeutic area notorious for clinical trial failures.

7.2 Critical Upcoming Catalysts and Development Milestones

The future valuation and trajectory of Envudeucitinib and Alumis are tied to several key, time-bound events.

• Primary Catalyst (Psoriasis): The single most important near-term catalyst is the release of topline data from the pivotal ONWARD1 and ONWARD2 trials in moderate-to-severe plaque psoriasis. This event, anticipated in the first quarter of 2026, will be the definitive readout on the drug's registrational efficacy and safety and its competitive profile versus placebo and apremilast. It represents the most significant potential value inflection point for the program.[1]
• Secondary Catalyst (SLE): The second major catalyst is the readout of topline data from the Phase 2b LUMUS trial in Systemic Lupus Erythematosus. This data, expected in the third quarter of 2026, will provide the first robust clinical validation of the drug's potential outside of dermatology and could significantly expand its long-term market opportunity.[1]
• Ongoing Data Flow: In the interim, continued data releases from the long-term extension studies (STRIDE OLE and eventually ONWARD3) will be important for reinforcing the narrative of long-term safety and durable, improving efficacy.

7.3 Long-Term Commercial Potential and Lifecycle Management Strategy

The long-term commercial potential for Envudeucitinib is substantial. Its success will be predicated on its ability to successfully navigate the final stages of clinical development and establish a "best-in-class" clinical profile. This will require the Phase 3 ONWARD program to not only meet its primary endpoints but also to generate data that demonstrates clinically meaningful differentiation from Sotyktu and other competitors. This differentiation will likely need to be on measures of higher-level efficacy, such as superior rates of PASI 90 or PASI 100, a faster onset of action, or a demonstrably cleaner long-term safety profile. A positive outcome in the LUMUS trial would unlock a second major market and solidify its status as a franchise-level asset. The successful development and timely transition to the once-daily modified-release formulation will be critical for maximizing patient uptake, ensuring long-term adherence, and defending its market position against competitors in the years following its potential launch.

7.4 Concluding Expert Assessment

Envudeucitinib (FTP-637) stands out as a scientifically well-designed, next-generation allosteric TYK2 inhibitor with a highly promising clinical profile established in its mid-stage program. The data generated to date, particularly the evidence of improving efficacy over 52 weeks in the Phase 2 OLE, provides a compelling and potentially unique point of differentiation that strongly supports a "best-in-class" narrative. The management at Alumis is executing a sound and aggressive late-stage development strategy, characterized by a robust pivotal program in psoriasis that includes a key active comparator, a high-reward pipeline expansion into SLE, and proactive lifecycle management.

The program's future, however, is contingent upon the outcome of the Phase 3 ONWARD trials. The data readout in the first quarter of 2026 will be the definitive moment for the asset. A successful outcome that confirms the high-level efficacy and clean safety seen in Phase 2 would position Envudeucitinib to be a major new oral therapy for autoimmune disease and a formidable challenger to Sotyktu for market leadership. Conversely, any failure to meet endpoints or the emergence of an unexpected safety signal would represent a significant setback. Based on the current body of evidence, Envudeucitinib is a high-potential asset on a clear path to a pivotal data readout that will ultimately determine its place in the therapeutic armamentarium for psoriasis and beyond.

Works cited

1. FTP-637 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 25, 2025, https://synapse.patsnap.com/drug/d6ac15173637407a80f7de60c3777e9e
2. Envudeucitinib - Wikipedia, accessed October 25, 2025, https://en.wikipedia.org/wiki/Envudeucitinib
3. Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/41061968/
4. Envudeucitinib - New Drug Approvals, accessed October 25, 2025, https://newdrugapprovals.org/2025/10/07/envudeucitinib/
5. Fronthera U.S. Pharmaceuticals LLC - Drug pipelines, Patents, Clinical trials - Synapse, accessed October 25, 2025, https://synapse.patsnap.com/organization/a694ee5052613a928172ad8e165bdf0a
6. Alumis Inc. (ALMS) Investor Outlook: Exploring A 328.89% Potential Upside In The Biotech Sector - DirectorsTalk Interviews, accessed October 25, 2025, https://www.directorstalkinterviews.com/alumis-inc-alms-investor-outlook-exploring-a-328-89-potential-upside-in-the-biotech-sector/4121220057
7. Stock Purchase Agreement among FL2021-001, Inc., FronThera International | ALUMIS INC., accessed October 25, 2025, https://contracts.justia.com/companies/alumis-inc-102857/contract/1286639/
8. TYK2 Kinase Inhibitors - Pipeline Insight 2022: Key Players Include Bristol-Myers Squibb, Oncostellae, Pfizer and Galapagos - ResearchAndMarkets.com - Business Wire, accessed October 25, 2025, https://www.businesswire.com/news/home/20220222005685/en/TYK2-Kinase-Inhibitors---Pipeline-Insight-2022-Key-Players-Include-Bristol-Myers-Squibb-Oncostellae-Pfizer-and-Galapagos---ResearchAndMarkets.com
9. Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD ..., accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/late-breaking-esk-001-phase-2-ole-data-presented-2025-aad-annual/
10. Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis, accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/alumis-completes-enrollment-pivotal-phase-3-onward-clinical/
11. Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study | Alumis Inc., accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/late-breaking-data-eadv-esk-001-oral-tyk2-inhibitor-treatment/
12. PsO Pipeline Update: Enrollment Complete in Phase 3 Program of Alumis' Oral TYK2 Inhibitor - The Dermatology Digest, accessed October 25, 2025, https://thedermdigest.com/pso-pipeline-update-enrollment-complete-in-phase-3-program-of-alumis-oral-tyk2-inhibitor/
13. What is the mechanism of action of Deucravacitinib?, accessed October 25, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-deucravacitinib
14. TYK2 Kinase Inhibitors - Pipeline Insight, 2025 - Research and Markets, accessed October 25, 2025, https://www.researchandmarkets.com/reports/5354311/tyk2-kinase-inhibitors-pipeline-insight-2025
15. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors - PMC, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9884727/
16. TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight, accessed October 25, 2025, https://www.prnewswire.com/news-releases/tyk2-inhibitors-market-to-drive-enormous-growth-by-2034-due-to-strong-pipeline-and-expanding-indications--delveinsight-302521600.html
17. SOTYKTU® (deucravacitinib) Mechanism of Action | for HCPs, accessed October 25, 2025, https://www.sotyktuhcp.com/mechanism-of-action
18. Takeda's oral TYK2 inhibitor matches biologic efficacy - Drug Discovery and Development, accessed October 25, 2025, https://www.drugdiscoverytrends.com/tak-279-an-oral-small-molecule-tyk2-inhibitor-offering-the-convenience-of-a-once-daily-pill-and-biologic-like-clinical-responses/
19. New TYK2 inhibitors: a growing race to top Bristol Myers | BioPharma Dive, accessed October 25, 2025, https://www.biopharmadive.com/news/tyk2-inhibitors-jak-protein-startups-biotech/633635/
20. Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting, accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/alumis-presents-positive-data-phase-2-clinical-trial-esk-001/
21. Alumis Completes Patient Enrollment in the Global LUMUS Phase ..., accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/alumis-completes-patient-enrollment-global-lumus-phase-2b-trial/
22. ANZCTR search results | Australian Clinical Trials, accessed October 25, 2025, https://www.australianclinicaltrials.gov.au/anzctr-search-results?search_text=&condition_category=all&condition_code=all&purpose_of_study=all&recruitment_status=all&recruitment_sites=all&phase=all&gender=all&healthy_volunteers=allðics_approval=Yes&page=504
23. A 2-part, randomised, double-blind, placebo-controlled ... - ANZCTR, accessed October 25, 2025, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885
24. Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005, accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/alumis-announces-positive-phase-1-data-cns-penetrant-tyk2/
25. envudeucitinib (ESK-001) News - LARVOL Sigma, accessed October 25, 2025, https://sigma.larvol.com/product.php?e1=934407&tab=newstrac
26. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40659116/
27. Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study - Alumis, accessed October 25, 2025, https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf
28. Envudeucitinib Demonstrates Sustained Efficacy and Safety in Moderate to Severe Plaque Psoriasis | Dermatology Times, accessed October 25, 2025, https://www.dermatologytimes.com/view/envudeucitinib-demonstrates-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis
29. Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis, accessed October 25, 2025, https://investors.alumis.com/news-releases/news-release-details/alumis-initiates-onward-phase-3-clinical-program-evaluating-esk/
30. PsO Pipeline Watch: Alumis Initiates Phase 3 Clinical Program Evaluating Its Oral TYK2 Inhibitor in Moderate-to-Severe Plaque PsO - The Dermatology Digest, accessed October 25, 2025, https://thedermdigest.com/pso-pipeline-watch-alumis-initiates-phase-3-clinical-program-evaluating-its-oral-tyk2-inhibitor-in-moderate-to-severe-plaque-pso/
31. Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis | Nasdaq, accessed October 25, 2025, https://www.nasdaq.com/articles/alumis-inc-completes-patient-enrollment-phase-3-onward-clinical-program-evaluating-esk-001
32. envudeucitinib (ESK-001) / Alumis - LARVOL DELTA, accessed October 25, 2025, https://delta.larvol.com/Products/?ProductId=ecec544f-b022-41f3-951e-b9b205e4f0ef
33. Psoriasis | New Drug Approvals, accessed October 25, 2025, https://newdrugapprovals.org/tag/psoriasis/
34. A $25 Billion Opportunity: Exploring the Enormous Market Impact of Deucravacitinib, accessed October 25, 2025, https://www.unibestpharm.com/A-25-Billion-Opportunity-Exploring-the-Enormous-Market-Impact-of-Deucravacitinib-id45051866.html
35. APPLICATION NUMBER: - 214958Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review - accessdata.fda.gov, accessed October 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214958Orig1s000MultidisciplineR.pdf
36. Bristol Myers bet pays off as psoriasis drug beats Amgen rival in study | BioPharma Dive, accessed October 25, 2025, https://www.biopharmadive.com/news/bristol-myers-tyk2-psoriasis-otezla/588288/
37. Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis - PMLiVE, accessed October 25, 2025, https://pmlive.com/pharma_news/bristol-myers-squibb-shares-five-year-results-for-sotyktu-in-plaque-psoriasis/
38. New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis, accessed October 25, 2025, https://news.bms.com/news/details/2025/New-Five-Year-Sotyktu-deucravacitinib-Data-Show-Consistent-Safety-and-Durable-Response-Rates-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspx